Sign In
Buy CTMX
$3.22
+0.0600 (+1.90%)
At Close: Jun 03, 2026
CytomX Therapeutics Announces Retirement of John A. Scarlett, M.D. from Board of Directors
08:15pm, Thursday, 14'th Apr 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that
CytomX Therapeutics Announces Retirement of Frederick W. Gluck from Board of Directors
08:15pm, Wednesday, 23'rd Mar 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that
CytomX Therapeutics to Present Updated Preclinical Data for Conditionally Activated Cytokine Program at AACR Annual Meeting 2022
08:00am, Thursday, 17'th Mar 2022
SOUTH SAN FRANCISCO, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that p
CytomX Therapeutics, Inc. 2021 Q4 - Results - Earnings Call Presentation
07:30pm, Friday, 04'th Mar 2022 Seeking Alpha
CytomX stock soars 16% as Q4 revenue rises 20% Y/Y
06:43pm, Wednesday, 02'nd Mar 2022 Seeking Alpha
CytomX Therapeutics <> rose following its FY21 results, which missed on analysts'' estimates.Q4 total revenues rose 20.2% Y/Y to $19.7M. The increase Q4 revenue was largely related…
Organogenesis, CytomX top healthcare gainers; Karyopharm Bright Health lead losers'' pack
03:01pm, Wednesday, 02'nd Mar 2022 Seeking Alpha
Gainers: Organogenesis (ORGO) +24%. CytomX Therapeutics (CTMX) +13%. X4 Pharmaceuticals (XFOR) +13%
The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi
12:50pm, Wednesday, 02'nd Mar 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours.
Stocks In Focus
Karyopharm Says FDA Mandates Additional Study For Expanding Selinexor Label To Include Advanced Endome
CytomX Therapeutics (CTMX) Q4 2021 Earnings Call Transcript
06:00am, Wednesday, 02'nd Mar 2022 The Motley Fool
CTMX earnings call for the period ending December 31, 2021.
CytomX Therapeutics (CTMX) Q4 2021 Earnings Call Transcript
06:00am, Wednesday, 02'nd Mar 2022 The Motley Fool
CTMX earnings call for the period ending December 31, 2021.
CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q4 2021 Results - Earnings Call Transcript
04:38am, Wednesday, 02'nd Mar 2022 Seeking AlphaCytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q4 2021 Results - Earnings Call Transcript
11:38pm, Tuesday, 01'st Mar 2022
CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q4 2021 Results - Earnings Call Transcript
CytomX Therapeutics (CTMX) Reports Q4 Loss, Lags Revenue Estimates
10:45pm, Tuesday, 01'st Mar 2022 Zacks Investment Research
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -60% and 32.47%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
CytomX Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Business Update
09:15pm, Tuesday, 01'st Mar 2022 GlobeNewswire Inc.
- Encouraging activity for CX-2029 in Phase 2 expansion study in squamous non-small cell lung cancer (sqNSCLC) reported in 2021 -
CytomX Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Business Update
09:15pm, Tuesday, 01'st Mar 2022 GlobeNewswire
- Encouraging activity for CX-2029 in Phase 2 expansion study in squamous non-small cell lung cancer (sqNSCLC) reported in 2021 -
CytomX Therapeutics (CTMX) Reports Q4 Loss, Lags Revenue Estimates
07:10pm, Tuesday, 01'st Mar 2022
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -60% and 32.47%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
